GSA Capital Partners’s VanEck Biotech ETF BBH Stock Holding History

GSA Capital Partners’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,234	Closed	-$423K	–	1717
2025 Q4	$423K	Buy	2,234 +985	+79%	+$182K	0.04%	930
2025 Q3	$207K	Buy	+1,249	New	+$204K	0.02%	1417
2023 Q3	–	Sell	-1,296	Closed	-$202K	–	1495
2023 Q2	$202K	Buy	+1,296	New	+$207K	0.02%	1262

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.1B AUM 16.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return

GSA Capital Partners's BBH Position: Q1 2026 in Review

GSA Capital Partners sold out of VanEck Biotech ETF (BBH) in Q1 2026, closing a stake of 2,234 shares — an estimated $423K sold.

GSA Capital Partners first reported a position in BBH in Q2 2023 and held it in 3 quarters. The position peaked at $423K in Q4 2025. 112 funds tracked by Wall St. Rank hold BBH as of Q1 2026.

GSA Capital Partners reported no remaining VanEck Biotech ETF position as of Q1 2026 after selling out during the quarter.
GSA Capital Partners sold 2,234 VanEck Biotech ETF shares in Q1 2026, an estimated $423K.
GSA Capital Partners first reported a position in VanEck Biotech ETF in Q2 2023 and held it in 3 quarters.
GSA Capital Partners's VanEck Biotech ETF position peaked at $423K in Q4 2025.
112 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.